BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230419T120000
DTEND;TZID=America/Toronto:20230419T170000
DTSTAMP:20260612T185808
CREATED:20230403T172621Z
LAST-MODIFIED:20230403T172621Z
UID:24364-1681905600-1681923600@scienceinboston.com
SUMMARY:Cell and Gene Therapy Catapult Boston Showcase
DESCRIPTION:Join like-minded local senior executives in a discussion with Cell and Gene Therapy Catapult’s own senior executives by attending this showcase event. We will be exploring ways in which your organizations can leverage CGT Catapult’s years of manufacturing expertise\, facilities\, resources and broader capabilities around increasing value of your asset(s) to expedite your access to European and global markets. \nWe invite you to attend this in-person event at the MassBio Hub in Boston (19th of April at 12pm)\, to learn how the Cell and Gene Therapy Catapult provides enabling tools and expertise to US-based AT developers to de-risk and accelerate the AT manufacturing pathway and route to clinic. \nAttendees will gain knowledge in: \n\nHow you can leverage 10 years of experience of supporting multiple AT companies to licensure to enable you to evolve from a CGT developer to a CGT manufacturer\, with expedited timelines and minimal resources\nHow your organization can access the biggest CGT cluster outside of the US\nHow non-UK companies can access world-class AT clinical research and support in the UK. You will also get exposed to how policies are attracting foreign companies to set-up clinical trials and manufacture in the UK\, what resources and expertise are available to allow you to best leverage the UK healthcare system.\nHow the CGT Catapult can support you to easily navigate the regulatory pathways for ATs in UK and the European Union (EU).\nSome lessons learned from our CGT Catapult team on navigating requirements relevant to production of clinical material for USA\, EU and UK.\nSnippets of wisdom from CGT Catapult’s partners on do’s and don’ts for implementation of in-house manufacturing capabilities.\n\nAgenda \n– 12pm: Arrival and lunch \n– 12.15pm: Welcome and opening remarks \n– 12.20pm: CGT Catapult’s unique model to accelerate AT developers’ pathway to establish mature GMP manufacturing capability – Sharon Brownlow\, Chief Business Officer; Mark Fuller\, Managing Director Manufacturing: \n\nTurning therapy developers into experienced therapy manufacturers in partnership\nSuccesses that provided the hindsight for our new partners\n\n– 1pm: Access Strategy: AT regulatory pathway\, clinical trials in UK and routes to successful market access – Jacqueline Barry\, Chief Clinical Officer: \n\nSet up clinical trials in the UK with confidence\nAuthorization or authorisation; making best use of acceleration pathways in the UK and EU\n\n– 1.40pm Q&A \n– 2pm Close of lunchtime event \n– 2pm – 5pm Opportunity for companies to have 121’s with CGT Catapult \nOn the day there will also be an opportunity for 121’s with the CGT Catapult teams. Please contact John Kelly at john.kelly@ct.catapult.org.uk to arrange. These can be before or after the lunchtime event. We will also be available on Thursday 20th if a more comprehensive discussion is preferred. \nWho should attend: \n\nCGT developers considering establishing GMP manufacture for supply of clinical trial and marketed product globally\nCGT organizations seeking comprehensive assistance for set-up of clinical trials and to ease navigation of regulatory pathways in UK and/or EU for their ATs.\n\nWe have limited capacity for this event\, so we invite you to register at your earliest convenience. \nVenue accessibility can be found here\, please contact us for more information.
URL:https://scienceinboston.com/event/cell-and-gene-therapy-catapult-boston-showcase/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
END:VCALENDAR